A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer

Abstract

Please cite this article as: Velenik V, Ocvirk J, Oblak I, Anderluh F. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer, European Journal of Surgical Oncology (2009Oncology ( ), doi: 10.1016Oncology ( /j.ejso.2009 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. M A N U S C R I P T A C C E P T E D ARTICLE IN PRESS

The outcome of 5-fluorouracil chemotherapy after the completion of neoadjuvant chemoradiotherapy, administered until 2 weeks before rectal cancer resection

“…Additional chemotherapeutic agents that have been studied in this context include oxaliplatin 13,14 and cetuximab. 15,16 These resulted in a pCR rate of 8e19%, which is lower than the 24.4% observed in our study. Although adding irinotecan 17 resulted in a higher pCR rate of 26%, the incidence of acute Grade 3e4 toxicity was as high as 42%, and hence, this therapy cannot be well tolerated by most patients.…”

Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer

“…Details of the eligibility criteria, pretreatment evaluation, RT, chemotherapy, cetuximab administration, and surgery have already been published and are briefly specified later (9,10,12,13).…”

The Addition of Target Therapy to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: A Review

“…Comparable results were presented by other trials [17,18,19]. Machiels et al [17] reported the clinical results of a phase I/II study combining cetuximab and standard CRT - 1.8 Gy, 5 days/week for 5 weeks, total dose 45 Gy, 3D conformal technique and capecitabine 650-825 mg/m 2 orally twice daily for the duration of RT - in the preoperative treatment of 40 patients with LARC.…”

“…In total, 37 patients underwent surgery and pCR was recorded in 5% ( n = 2) of cases. Velenik et al [18] assessed neoadjuvant cetuximab with fluoropyrimidine-based CRT (capecitabine 825 mg/m 2 twice daily with RT of 45 Gy) in 37 LARC patients. Two patients presented with grade 3 acneiform rash and 2 patients with grade 3 diarrhea.…”